From: A systematic review of economic evaluations of cervical cancer screening methods
Study | Dominant screening technology/method | Outcome measure | I$ (2020) |
Legood et al. 2005 [20] | VIA | Cost/positive case detected | 482.84 |
Xie et al. 2017 [33] | VIA | Cost/positive case detected | 1,448.04 |
Campos et al. 2015 [34] | VIA at LTFU 60% | Cost/YLS | 311.94 |
VIA at LTFU 40% | Cost/YLS | 181.96 | |
Deroche et al. 2015 [35] | VIA | Cost/positive case detected | 13.67 |
Chauhan et al. 2020 [36] | VIA | Cost/QALY gained | 772.86 |
Shi et al. 2011 [37] | Clinician provided careHPV @ 0.5 pg/ml | Cost/YLS | 2,879.31 |
Campos et al. 2015 [67] | HPV DNA testing at LTFU 10% | Cost/YLS | 233.95 |
Sharma et al. 2016 [38] | HPV DNA testing every 5 years | Cost/YLS | 1,355,400.48 |
Kim et al. 2005 [39] | HPV triage (in the Netherlands) | Cost/YLS | 4,596.13 |
HPV triage (in France) | Cost/YLS | 3,414.27 | |
HPV triage (Italy) | Cost/YLS | 1,969.77 | |
Cromwell et al. 2021 [22] | HPV DNA testing every 4 years | Cost/CIN2 detected | |
Campos et al. 2015 [34] | CareHPV (cervical sampling) (in India) | Cost/YLS | 138.76 |
CareHPV (cervical sampling) (in Nicaragua) | Cost/YLS | 3,744.45 | |
CareHPV (cervical sampling) (in Uganda) | Cost/YLS | 8,930.80 | |
Termrungruanglert et al. 2017 [50] | hrHPV testing every 5 years | Cost/positive case detected | 1,410.04 |
Zhao et al. 2019 [41] | CareHPV DNA testing every 3 or 5 years | Cost/positive case detected | 3,038.76 |
Gamboa et al. 2018 [68] | HPV DNA testing every 5 years | Cost/YLS | 3,119.19 |
Jansen et al. 2020 [69] | hrHPV testing | Cost/YLG | 13,578.30 |
hrHPV testing | Cost/QALY gained | 15,242.86 | |
Ma et al. 2019 [44] | HPV DNA testing every 5 years | Cost/YLS | 7,690.48 |
HPV DNA testing every 3 years | Cost/YLS | 10,122.28 | |
Sroczynski et al. 2010 [70] | HPV DNA testing every 2 years | Cost/YLG | 138,829.99 |
Goldie et al. 2005 [8] | HPV DNA testing (in Kenya) | Cost/YLS | 56,318.49 |
HPV DNA testing (in India) | Cost/YLS | 283.16 | |
HPV DNA testing (in Peru) | Cost/YLS | 644.44 | |
HPV DNA testing (in South Africa) | Cost/YLS | 744.64 | |
HPV DNA testing (in Thailand) | Cost/YLS | 602.77 | |
Campos et al. 2018 [71] | HPV DNA testing every 2 years | Cost/YLS | 2,848.58 |
Study | Dominant screening strategy | Outcome measure | I$ (2019) |
de Kok et al. 2012 [47] | Primary HPV screening | Not reported | |
Campos et al. 2014 [46] | HPV-DNA screening every 5 years followed by cryotherapy (screen and treat) | Cost/YLS | 21,511.43 |
Pista et al. 2019 [48] | HPV testing with HPV 16/18 genotyping and cytology triage | Cost/CIN2 detected | 17,403.27 |
Skroumpelos et al. 2019 [49] | Primary HPV16/18 genotyping every 3 years | Cost/death averted | 1,637,776.08 |
Termrungruanglert et al. 2019 [50] | HPV primary screening triage with p16/Ki-67 | Cost/detected case | 1,660.20 |
Vassilakos et al. 2019 [51] | Self-HPV testing followed by Pap testing | Cost/QALY gained | 12,678.37 |
Campos et al. 2018 [21] | HPV testing followed by cryotherapy | Cost/YLS | 13,924.77 |
Mezei et al. 2018 [52] | Community based self-collected HPV DNA testing followed by VIA triage | Cost/YLS | 10,673.49 |
Lew et al. 2018 [53] | HPV testing and HPV 16/18 genotyping every 5 years | Not reported | Not reported |
Barre et al. 2017 [54] | Primary HPV testing and HPV 16/18 genotyping every 5 years | Coslt/LY | 2,674.12 |
Campos et al. 2017 [67] | HPV DNA testing followed by cryotherapy | Cost/YLS | 27,288.02 |
Jin et al. 2016 [56] | Primary HPV DNA testing followed by followed by cytology for HPV-positive women. Testing every 5 years | Marginal cost/case detected | 170,305.76 |
Burger et al. 2012 [57] | Unvaccinated women: cytology followed by switching to HPV testing at 34 every 4 years | Cost/YLS | 23,743.81 |
Vaccinated women: cytology followed by switching to HPV testing at 31, every 6 years | Cost/YLS | 65,500.18 | |
Flores et al. 2010 [58] | Pap and clinician-HPV test (30–80 years) | Not reported | |
Sroczynski et al. 2011 [45] | HPV triage,1 year, age: 30 years; prior Pap, 1 year | Cost/LYG | 222,752.67 |
Kim et al. 2005 [39] | UK: combination testing, 5 years | Cost/YLS | |
Sherlaw-Johnson et al. 2004 [59] | HPV triage with LBC, 5 years | Cost/YLS | 6,324.82 |
Primary HPV with LBC, 5 years | Cost/YLS | 7,671.45 | |
Combined cytology and HPV with LBC, 5 years | Cost/YLS | 46,663.86 | |
Combined cytology with LBC, 3 years | Cost/YLS | 780,481.31 | |
Chow et al. 2010 [60] | HPV testing followed by Pap smear triage every 5 years | Cost/QALY gained | 2,940.98 |
Campos et al. 2012 [46] | Primary HPV-based testing strategies | Cost/YLS | 584.88 |
Beal et al. 2014 [61] | hrHPV with molecular triage | Cost/prevented missed case | 580.76 |
Tantitamit et al. 2019 [62] | HPV genotyping with reflex dual stain cytology | Cost/QALY gained | 837.20 |
Vale et al. 2021 [63] | hrHPV testing with LBC triage | Cost/detection of CIN2/3 | 36.26 |
Berkhof et al. 2010 [64] | HPV DNA testing every 5 years with cytology triage | Cost/QALY gained | 25,783.00 |
Vanni et al. 2011 [65] | HPV DNA testing followed by cytology triage every year | Cost/YLS | 770.83 |
Lew et al. 2016 [53] | 5-yearly HPV screening with partial genotyping for HPV16/18 and referral to colposcopy and cytological triage of other oncogenic types | Not reported | X |
Felix et al. 2016 [66] | Co-testing using LBC and HPV 16 18/45 genotyping | Cost/QALY gained | 2,550.16 |